NDAORALCAPSULEPriority Review
Approved
Sep 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
6/8 — Strong
Priority Review
GAVRETO (pralsetinib) by Rigel Pharmaceuticals is rearranged during transfection (ret) inhibitors [moa]. Approved for medullary thyroid cancer, non-small cell lung cancer. First approved in 2020.
Drug data last refreshed 20h ago
Mechanism of Action
Rearranged during Transfection (RET) Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (2)
Worked on GAVRETO at Rigel Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.